博雅生物取得破伤风人免疫球蛋白药品注册证书

Core Viewpoint - The company, Boya Bio-Pharmaceutical (300294.SZ), has received the Drug Registration Certificate for Tetanus Human Immunoglobulin from the National Medical Products Administration [1] Company Summary - Boya Bio-Pharmaceutical has successfully obtained regulatory approval for its Tetanus Human Immunoglobulin product, which may enhance its product portfolio and market position [1]